Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Taymaa May; Marcus Bernardini; Stephanie Lheureux; Katja K H Aben; Elisa V Bandera; Matthias W Beckmann; Javier Benitez; Andrew Berchuck; Line Bjørge; Michael E Carney; Daniel W Cramer; Anna deFazio; Thilo Dörk; Diana M Eccles; Michael Friedlander; María Jose García; Ellen L Goode; Alexander Hein; Claus K Høgdall; Allan Jensen; Sharon Johnatty; Catherine J Kennedy; Lambertus A Kiemeney; Susanne K Kjær; Jolanta Kupryjańczyk; Keitaro Matsuo; Valerie McGuire; Francesmary Modugno; Lisa E Paddock; Tanja Pejovic; Catherine M Phelan; Marjorie J Riggan; Cristina Rodriguez-Antona; Joseph H Rothstein; Weiva Sieh; Honglin Song; Kathryn L Terry; Anne M van Altena; Adriaan Vanderstichele; Ignace Vergote; Liv Cecilie Vestrheim Thomsen; Penelope M Webb; Nicolas Wentzensen; Lynne R Wilkens; Argyrios Ziogas; Haiyan Jiang; Alicia Tone; Ovarian Cancer Association and the Australian Ovarian Cancer Study Group

doi:10.1503/cjs.017020

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Taymaa May^*, Marcus Bernardini, Stephanie Lheureux, Katja K H Aben, Elisa V Bandera, Matthias W Beckmann, Javier Benitez, Andrew Berchuck, Line Bjørge, Michael E Carney, Daniel W Cramer, Anna deFazio, Thilo Dörk, Diana M Eccles, Michael Friedlander, María Jose García, Ellen L Goode, Alexander Hein, Claus K Høgdall, Allan JensenSharon Johnatty, Catherine J Kennedy, Lambertus A Kiemeney, Susanne K Kjær, Jolanta Kupryjańczyk, Keitaro Matsuo, Valerie McGuire, Francesmary Modugno, Lisa E Paddock, Tanja Pejovic, Catherine M Phelan, Marjorie J Riggan, Cristina Rodriguez-Antona, Joseph H Rothstein, Weiva Sieh, Honglin Song, Kathryn L Terry, Anne M van Altena, Adriaan Vanderstichele, Ignace Vergote, Liv Cecilie Vestrheim Thomsen, Penelope M Webb, Nicolas Wentzensen, Lynne R Wilkens, Argyrios Ziogas, Haiyan Jiang, Alicia Tone, Ovarian Cancer Association and the Australian Ovarian Cancer Study Group

^*Corresponding author af dette arbejde

Abstract

BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.

METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.

RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.

CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Originalsprog	Engelsk
Tidsskrift	Canadian journal of surgery. Journal canadien de chirurgie
Vol/bind	66
Udgave nummer	3
Sider (fra-til)	E310-E320
ISSN	0008-428X
DOI	https://doi.org/10.1503/cjs.017020
Status	Udgivet - 2023

Adgang til dokumentet

10.1503/cjs.017020

Andre filer og links

Link to publication in Scopus

Citationsformater

May, T., Bernardini, M., Lheureux, S., Aben, K. K. H., Bandera, E. V., Beckmann, M. W., Benitez, J., Berchuck, A., Bjørge, L., Carney, M. E., Cramer, D. W., deFazio, A., Dörk, T., Eccles, D. M., Friedlander, M., García, M. J., Goode, E. L., Hein, A., Høgdall, C. K., ... Ovarian Cancer Association and the Australian Ovarian Cancer Study Group (2023). Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis. Canadian journal of surgery. Journal canadien de chirurgie, 66(3), E310-E320. https://doi.org/10.1503/cjs.017020

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis. / May, Taymaa; Bernardini, Marcus; Lheureux, Stephanie et al.
I: Canadian journal of surgery. Journal canadien de chirurgie, Bind 66, Nr. 3, 2023, s. E310-E320.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

May, T, Bernardini, M, Lheureux, S, Aben, KKH, Bandera, EV, Beckmann, MW, Benitez, J, Berchuck, A, Bjørge, L, Carney, ME, Cramer, DW, deFazio, A, Dörk, T, Eccles, DM, Friedlander, M, García, MJ, Goode, EL, Hein, A, Høgdall, CK, Jensen, A, Johnatty, S, Kennedy, CJ, Kiemeney, LA, Kjær, SK, Kupryjańczyk, J, Matsuo, K, McGuire, V, Modugno, F, Paddock, LE, Pejovic, T, Phelan, CM, Riggan, MJ, Rodriguez-Antona, C, Rothstein, JH, Sieh, W, Song, H, Terry, KL, van Altena, AM, Vanderstichele, A, Vergote, I, Thomsen, LCV, Webb, PM, Wentzensen, N, Wilkens, LR, Ziogas, A, Jiang, H, Tone, A & Ovarian Cancer Association and the Australian Ovarian Cancer Study Group 2023, 'Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis', Canadian journal of surgery. Journal canadien de chirurgie, bind 66, nr. 3, s. E310-E320. https://doi.org/10.1503/cjs.017020

@article{48cab2a73efb44eab588c450b646db68,

title = "Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis",

abstract = "BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.",

author = "Taymaa May and Marcus Bernardini and Stephanie Lheureux and Aben, {Katja K H} and Bandera, {Elisa V} and Beckmann, {Matthias W} and Javier Benitez and Andrew Berchuck and Line Bj{\o}rge and Carney, {Michael E} and Cramer, {Daniel W} and Anna deFazio and Thilo D{\"o}rk and Eccles, {Diana M} and Michael Friedlander and Garc{\'i}a, {Mar{\'i}a Jose} and Goode, {Ellen L} and Alexander Hein and H{\o}gdall, {Claus K} and Allan Jensen and Sharon Johnatty and Kennedy, {Catherine J} and Kiemeney, {Lambertus A} and Kj{\ae}r, {Susanne K} and Jolanta Kupryja{\'n}czyk and Keitaro Matsuo and Valerie McGuire and Francesmary Modugno and Paddock, {Lisa E} and Tanja Pejovic and Phelan, {Catherine M} and Riggan, {Marjorie J} and Cristina Rodriguez-Antona and Rothstein, {Joseph H} and Weiva Sieh and Honglin Song and Terry, {Kathryn L} and {van Altena}, {Anne M} and Adriaan Vanderstichele and Ignace Vergote and Thomsen, {Liv Cecilie Vestrheim} and Webb, {Penelope M} and Nicolas Wentzensen and Wilkens, {Lynne R} and Argyrios Ziogas and Haiyan Jiang and Alicia Tone and {Ovarian Cancer Association and the Australian Ovarian Cancer Study Group}",

note = "{\textcopyright} 2023 CMA Impact Inc. or its licensors.",

year = "2023",

doi = "10.1503/cjs.017020",

language = "English",

volume = "66",

pages = "E310--E320",

journal = "Canadian journal of surgery. Journal canadien de chirurgie",

issn = "0008-428X",

publisher = "Canadian Medical Association",

number = "3",

}

TY - JOUR

T1 - Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma

T2 - an international multicentre analysis

AU - May, Taymaa

AU - Bernardini, Marcus

AU - Lheureux, Stephanie

AU - Aben, Katja K H

AU - Bandera, Elisa V

AU - Beckmann, Matthias W

AU - Benitez, Javier

AU - Berchuck, Andrew

AU - Bjørge, Line

AU - Carney, Michael E

AU - Cramer, Daniel W

AU - deFazio, Anna

AU - Dörk, Thilo

AU - Eccles, Diana M

AU - Friedlander, Michael

AU - García, María Jose

AU - Goode, Ellen L

AU - Hein, Alexander

AU - Høgdall, Claus K

AU - Jensen, Allan

AU - Johnatty, Sharon

AU - Kennedy, Catherine J

AU - Kiemeney, Lambertus A

AU - Kjær, Susanne K

AU - Kupryjańczyk, Jolanta

AU - Matsuo, Keitaro

AU - McGuire, Valerie

AU - Modugno, Francesmary

AU - Paddock, Lisa E

AU - Pejovic, Tanja

AU - Phelan, Catherine M

AU - Riggan, Marjorie J

AU - Rodriguez-Antona, Cristina

AU - Rothstein, Joseph H

AU - Sieh, Weiva

AU - Song, Honglin

AU - Terry, Kathryn L

AU - van Altena, Anne M

AU - Vanderstichele, Adriaan

AU - Vergote, Ignace

AU - Thomsen, Liv Cecilie Vestrheim

AU - Webb, Penelope M

AU - Wentzensen, Nicolas

AU - Wilkens, Lynne R

AU - Ziogas, Argyrios

AU - Jiang, Haiyan

AU - Tone, Alicia

AU - Ovarian Cancer Association and the Australian Ovarian Cancer Study Group

PY - 2023

Y1 - 2023

N2 - BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

AB - BACKGROUND: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.METHODS: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.RESULTS: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.CONCLUSION: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

UR - http://www.scopus.com/inward/record.url?scp=85166274935&partnerID=8YFLogxK

U2 - 10.1503/cjs.017020

DO - 10.1503/cjs.017020

M3 - Journal article

C2 - 37369443

SN - 0008-428X

VL - 66

SP - E310-E320

JO - Canadian journal of surgery. Journal canadien de chirurgie

JF - Canadian journal of surgery. Journal canadien de chirurgie

IS - 3

ER -

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater